TIDMITX
RNS Number : 9590Q
Itaconix PLC
18 September 2017
18 September 2017
Itaconix plc
Unaudited interim results for the 6 month period to 30 June
2017
Progress in achieving commercial milestones and building
relationships with key industry players
Itaconix plc (AIM: ITX) a leading innovator in sustainable
specialty polymers ("Itaconix", the "Company" or the "Group"),
today announces its unaudited interim results for the 6 month
period to 30 June 2017.
Business Highlights (including after the period end)
-- Croda - exclusive global supply and joint marketing agreement
signed in January to commercialise the odour removal additive
Itaconix(R) ZINADOR(TM) 22L ("ZINADOR") in household, municipal,
animal and industrial applications
-- AkzoNobel - JDA signed in January to collaborate on
commercialisation of itaconic acid technology in specific
applications:
o In July, application agreement signed to develop new products
for use in the coatings and construction industries
o In September, application agreement signed to evaluate and
develop new chelates based on Itaconix(R) DSP(TM) and Itaconix(R)
CHT(TM) in consumer and industrial detergent and cleaner
applications, under AkzoNobel's Dissolvine(R) brand
-- RevCare(TM) NE:
o Direct relationships established with a number of the global
cosmetics houses
o Distribution arrangements set up in USA, Germany, France,
Italy, Spain, Poland, South Korea and Japan
o First consumer hair styling product containing RevCare(TM) NE
launched in Italy
The business also continues to work with other non-disclosed
industry players, including funded collaborations, to develop new
ingredients for a range of applications in its key markets of
personal and consumer health care, homecare and industrial
products.
Operational and Financial Highlights - Continuing Operations
-- From 1 March the business was re-launched as a specialty
chemicals group and the Company's name was changed to Itaconix plc,
reflecting its core product platform of novel bio-based polymers
from itaconic acid
-- Organisational and operational efficiencies were implemented
in May. The resultant cost base savings are expected to be at least
GBP1m per annum from 2018
-- Cash, cash equivalents and short term investments of GBP5.4m
at 30 June 2017 (30 June 2016: GBP6.1m, 31 December 2016:
GBP8.8m)
-- Revenue from specialty chemicals sales increased to GBP0.3m
(30 June 2016: nil) and gross profit improved to GBP0.1m (30 June
2016: nil)
-- The loss before taxation for the period was unchanged at
GBP2.5m (30 June 2016: GBP2.5m), as was the loss after taxation at
GBP2.2m (30 June 2016: GBP2.2m)
-- R&D tax credits were GBP0.3m (30 June 2016: GBP0.2m).
Outlook
The re-launch of the business as Itaconix plc, focused on a
specialty chemicals portfolio (primarily the itaconic acid
bio-based specialty polymer platform) signals a new phase for the
Group. The Board believes there is good reason to be positive about
the outlook for the business. Revenues and gross profit for the
period have matched reported full year 2016, and the cost base has
been restructured and stabilised. The implementation of the Group's
strategy is starting to be reflected in financial performance, and
our objective is to continue to drive product revenue starts and
growth.
For further information please contact:
+44 (0) 1244 283
Itaconix 500
Kevin Matthews / Rob Cridland
+44 (0) 207 496
N+1 Singer 3000
Richard Lindley / Liz Yong (Corporate
Finance)
Nick Owen (Corporate Broking)
Hudson Sandler
Charlie Jack / Emily Dillon +44 (0) 207 796 4133
The half-yearly report and this announcement will be available
shortly on the Company's website: www.itaconix.com
Cautionary Statement
Information in this announcement is based upon unaudited
management accounts and, in addition, some of the statements made
are forward looking. Such statements are based on current
expectations at the date of this announcement and are subject to a
number of risks and uncertainties that could cause actual events or
results to differ materially from any expected future events or
results referred to in these forward looking statements. The
Company and its directors undertake no obligation to update or
revise forward looking statements to reflect any change in
expectations or any change in events, conditions or
circumstances.
Chief Executive's Statement
Business Overview
Following the acquisition and successful integration of Itaconix
Corporation and the completion of the divestment of the nicotine
gum business in 2016, the Group was re-launched in March 2017 under
the name Itaconix plc. As a pure-play specialty chemicals business,
the Group is now focused on supplying high performance, cost
effective and sustainable ingredients that are key components of
the consumer and industrial products made by its customers in the
personal and consumer health care, homecare and industrial
sectors.
Itaconix's strategy is to use its expertise in the design and
manufacture of high performance polymers to develop ingredients
that offer cost competitive performance improvements to its
customers' products. The majority of Itaconix's products are
bio-based, being derived from itaconic acid which in turn is
derived from corn starch. Therefore, these products are sustainably
sourced and help our customers improve the sustainability of their
own consumer products. Itaconix is a leading innovator in
sustainable specialty polymers from itaconic acid, combining the
versatile chemistry of itaconic acid with breakthrough
manufacturing economics based on a patented process.
Increasing consumer expectations, regulatory changes and
environmental best practice are resulting in major consumer product
companies seeking to improve product performance whilst replacing
petrochemical ingredients with sustainable alternatives. This trend
is widespread, with notable examples being Unilever, P&G and
L'Oreal, and many of the major specialty chemicals companies have
signed up to an initiative called "Together for Sustainability". We
believe that Itaconix is strategically well aligned with this long
term trend and positioned to play a significant future role in the
redesign of many supply chains to improve the environmental
sustainability of consumer products.
We have a portfolio of functional ingredients that are starting
to be used in a range of consumer products including laundry
detergents, auto dish wash (ADW) tablets, odour management products
and hair styling. Itaconix also uses its specialty polymers to
encapsulate and protect sensitive or unstable active ingredients
that can be used in everyday products; examples include bleach
actives used in laundry and ADW, and fragrances.
Currently, we estimate that our product range is addressing
global markets with an estimated aggregate turnover of $1.4bn pa,
but as a small growing company we recognise the challenge of
effectively accessing these markets in a timely fashion. To address
this, Itaconix is actively building collaborative partnerships with
leading industry players such as AkzoNobel, Croda and Solvay, with
the aim of accelerating market adoption of Itaconix's products.
In October 2016 we set out a series of milestones that we
expected to achieve in 2017, with the overarching intention to
secure partnership deals and revenue starts; in effect establishing
channels to market and first sales of products. Whilst some of
these milestones have been delayed compared to our initial
expectations, we are pleased with overall progress. The table below
provides a summary to date.
Milestones in next
12 months (from Oct 2017 milestone status
Product 2016) to date
1 Itaconix(R) Revenue growth in H1 revenue mainly
DSP(TM),CHT(TM) 2017. based on Itaconix(R)
Adoption in ADW by DSP(TM). AkzoNobel
major private label Chelates Application
house or equivalent Agreement
2 RevCare Appointment of distributors Distributors appointed
NE (TM) First sales and revenue in multiple jurisdictions.
growth in 2017 First sales with
use in first consumer
product.
3 Itaconix Sign commercial partner Croda Supply and
(R) ZINADOR(TM) Revenue growth in Joint Marketing
homecare and industrial Agreement. First
sales to Croda,
product launched
globally
4 Licences First revenues from Solvay notified
(Royalty) Solvay PAP licence ITX of first Eureco(TM)
Secure new licences RP103 sales in H2
5 RevCoat Appointment of distributors -
Bond (TM) Sign-up lead customer
and revenue growth
in 2017
6 Itaconix(R) Sign-up lead customer, AkzoNobel Performance
TSI(TM), first sales Additives Application
XDP(TM) Agreement
7 RevCap Sign two lead customers -
FE(TM) Revenue growth
----------------- ---------------------------- ----------------------------
As a specialty chemicals business, Itaconix expects to earn
gross margins of around 40% once market access is secured. For the
first time, we are pleased to report actual sales revenue in the
period at gross margins in excess of 40%. We have also realigned
our cost base to support the commercialisation of our existing
product portfolio, refocusing more of our product development
resource on supporting our customers and delivering commercial
goals.
Although we have made a meaningful start, the most significant
commercial challenge facing the business remains getting our
products to their respective markets to generate revenue as quickly
as practicable. We believe that the business will continue to
deliver further milestones this year and, given the developments
and changes made in 2017 to date, will be well positioned for
further revenue growth in 2018.
Milestone Details
Including developments after the period end, management is
pleased to report that Itaconix has continued to deliver on its
strategic milestones:
Itaconix(R) DSP(TM), CHT(TM) - AkzoNobel - Chelates Application
Agreement - after the period end on 5 September 2017, Itaconix
announced the signing of a second application agreement with
AkzoNobel's Specialty Chemicals unit to evaluate and develop
innovative bio-based chelates for use in the consumer and
industrial detergents and cleaners markets, to be marketed under
AkzoNobel's Dissolvine(R) brand. AkzoNobel is a world leader in
chelation products and bio-based chelates such as Itaconix(R)
DSP(TM) and CHT(TM) show promise for use in laundry detergents,
bathroom cleaners and other consumer and commercial cleaning
products, and are replacements for phosphates which are being
phased out due to environmental concerns.
RevCare(TM) NE - during the period, distribution relationships
have been established in the USA, Germany, France, Italy, Spain,
Poland and the key Asian markets of South Korea and Japan. In
parallel Itaconix has developed direct relationships with a number
of the global cosmetics houses. We currently have in excess of 50
active evaluations ongoing with customers, and the product has
already been adopted for use in a hair-styling product in Italy;
the first consumer product containing RevCare(TM) NE.
Itaconix (R) ZINADOR(TM) - Croda - as announced on 23 January
2017, Itaconix signed an exclusive global supply and joint
marketing agreement with Croda in respect of its polymer-based
odour removal additive ZINADOR. Using its patented itaconic acid
polymer technology, Itaconix is delivering a major cost-effective
breakthrough to a global odour neutralisation industry that is
seeking new high performance solutions. As a 100% bio-based product
that is readily soluble in water and does not leave any residual
materials, ZINADOR meets key unmet customer needs in the growing
consumer and industrial markets for odour control. Under the terms
of the agreement, the parties are working together to grow and
supply worldwide demand for ZINADOR. Itaconix is producing ZINADOR
for Croda, which is marketing and selling ZINADOR in household,
municipal, animal and industrial applications, subject to certain
terms and conditions. Itaconix will continue providing its
technical and marketing expertise to jointly expand applications
and geographic opportunities for ZINADOR with Croda. We have
already satisfied the first order from Croda following their global
launch of ZINADOR in H1 2017.
Licences - Solvay - Solvay has notified us that it has made its
first sales of the encapsulated specialty PAP bleach product
Eureco(TM) RP103, manufactured using technology Itaconix licensed
to it in 2014. We would expect these sales to translate into a
small royalty income from H2 2017.
Itaconix(R) TSI(TM), XDP(TM) - AkzoNobel - JDA and Performance
Additives Application Agreement - as announced on 27 January 2017,
Itaconix signed a joint development agreement with AkzoNobel to
advance commercial collaborations in certain applications for its
itaconic acid polymer technology platform. The agreement
establishes a broad operating framework for the parties to jointly
identify, develop and commercialise new polymers using Itaconix's
patented technology. After the period end on 26 July 2017, Itaconix
announced the signing of its first application area agreement with
AkzoNobel's Performance Additives unit, developing applications for
Itaconix bio-based polymers to be used in the coatings and
construction industries, representing large and important markets
for the Group's future product portfolio.
In addition to the milestones summarised above, the business
also continues to work with other non-disclosed industry players,
including funded collaborations, to develop new products in a range
of applications in its key markets of personal and consumer health
care, homecare and industrial products.
Organisational Enhancement
Change of name - as announced on 1 March 2017, the Company's
name changed from Revolymer plc to Itaconix plc. In addition, the
Company's UK operating company was renamed Itaconix (U.K.) Limited.
These changes mark the re-launch of the Group as a specialty
chemicals business based on polymers that deliver high performance,
cost effective and sustainable ingredients for the products made by
our customers in the personal and consumer health care, homecare
and industrial sectors.
Operational update - as announced on 18 May 2017, Itaconix
confirmed that following the acquisition and integration of
Itaconix Corporation in the USA, it was implementing operational
changes to the Group. Resources are now more focused on
successfully executing the Group's strategy to launch and grow the
sales of its products, primarily in the global personal care and
homecare markets, including the development of application data
that provides clear evidence of the material benefits of using
Itaconix's products and how they can be best formulated into end
consumer products. Given the Group's established product portfolio
and evolving sales and marketing focus, its need for new product
development has become more defined and targeted to customer
requirements. Accordingly, it was appropriate to resize the R&D
team, which is resulting in operational efficiencies. Whilst the
full financial effect of these changes will not be achieved
immediately, with the net cash impact only partially realised in
2017, the positive net cash impact is expected to be over GBP1m per
annum from 2018.
Financial Overview
Continuing Operations
Cash, cash equivalents and short term investments on hand at the
period end were GBP5.4m (30 June 2016: GBP6.1m, 31 December 2016:
GBP8.8m).
Revenue for the period increased to GBP0.3m (30 June 2016: nil,
31 December 2016: GBP0.3m) and gross profit improved to GBP0.1m (30
June 2016: nil, 31 December 2016: GBP0.1m). Following the
divestment of the nicotine gum business in 2016, this revenue and
gross profit is for the first time from the sales of specialty
chemicals products only, and performance for the first half of 2017
is the same as for reported full year 2016 after the mid year
acquisition of Itaconix Corporation.
Administrative expenses for the period were GBP2.7m (30 June
2016: GBP2.5m, 31 December 2016: GBP5.3m). These included running
the acquired US business that was not in the Group for the majority
of the first half of 2016.
The loss before taxation for the period was unchanged at GBP2.5m
(30 June 2016: GBP2.5m, 31 December 2016: GBP5.6m), as was the loss
after taxation at GBP2.2m (30 June 2016: GBP2.2m, 31 December 2016:
GBP5.1m), after R&D tax credits of GBP0.3m (30 June 2016:
GBP0.2m, 31 December 2016: GBP0.5m). The investment in associate
undertakings (i.e. the holding in Alkalon A/S, the acquirer in 2016
of the nicotine gum business) increased to GBP0.2m (30 June 2016:
nil, 31 December 2016: GBP0.1m), reflecting a partial reversal of
the impairment recognised in 2016 as a result of the improved
financial position of the company, a pro rata participation in a
DKK 3.5m capital raise, and equity accounting for Itaconix's share
of a small profit in the period. The Group acquired a further 2%
holding in the company at no additional cost following the delivery
of certain commercial milestones during the period.
Discontinued Operations
The loss from discontinued operations (i.e. the nicotine gum
business disposed of in 2016) was nil (30 June 2016: GBP0.4m, 31
December 2016: GBP0.6m), and the cash outflow from discontinued
operations was nil (30 June 2016: GBP0.6m, 31 December 2016:
GBP1.3m), as a result of the disposal of this loss making business
in 2016.
Outlook
The re-launch of the business as Itaconix plc, focused on a
specialty chemicals portfolio (primarily the itaconic acid
bio-based polymer platform) signals a new phase for the Group. The
Board believes there is good reason to be positive about the
outlook for the business. Revenues and gross profit for the period
have matched reported full year 2016, and the cost base has been
restructured and stabilised. The implementation of the Group's
strategy is starting to be reflected in financial performance, and
our objective is to continue to drive product revenue starts and
growth.
Condensed consolidated income statement and statement of
comprehensive income
For the six months ended 30 June 2017
Unaudited Unaudited Audited
6 Months 6 Months Year
to 30 to 30 to 31
June June December
2017 2016 2016
Restated
Notes GBP000 GBP000 GBP000
Continuing operations
Revenue 7 325 25 285
Cost of sales 5 (179) (19) (230)
--------- --------- ---------
Gross profit 146 6 55
Other operating income 5 2 11 38
Administrative expenses 5 (2,669) (2,523) (5,275)
--------- --------- ---------
Group operating loss 5 (2,521) (2,506) (5,182)
Finance income - 35 51
Share of profit / (loss)
of associate 26 - (508)
--------- --------- ---------
Loss before tax from
continuing operations (2,495) (2,471) (5,639)
Taxation credit 6 276 232 531
--------- --------- ---------
Loss for the period from
continuing operations (2,219) (2,239) (5,108)
Loss after tax for the
period from discontinued
operations 8 - (418) (608)
--------- --------- ---------
Loss for the period (2,219) (2,657) (5,716)
Other comprehensive income,
net of income tax
Items that may be reclassified
subsequently to profit
or loss:
Exchange differences
on translated foreign
operations (425) 856 1,439
--------- --------- ---------
Total comprehensive loss
for the period (2,644) (1,801) (4,277)
========= ========= =========
Basic and diluted loss
per share 14 2.8p 3.1p 8.2p
========= ========= =========
Basic and diluted loss
per share from continuing
operations 14 2.8p 2.3p 7.3p
========= ========= =========
The discontinued operations relate to the nicotine gum business,
the divestment of which was completed on 31 October 2016.
The continuing operations relate to the specialty chemicals
business of the Group, including Itaconix Corporation acquired on
20 June 2016.
Condensed consolidated statement of financial position
As at 30 June 2017
Unaudited Unaudited Audited
As at As at As at
30 June 30 June 31 December
2017 2016 2016
Restated Restated
Notes GBP000 GBP000 GBP000
Non-current assets
Property, plant and equipment 9 1,129 563 803
Intangible assets 10 9,477 9,550 10,124
Investment in associate
undertakings 13 237 - 145
--------- --------- -----------
10,843 10,113 11,072
Current assets
Inventories 253 544 210
Trade and other receivables 1,174 1,267 835
Investments 4 - 6,000 -
Cash and cash equivalents 4 5,379 97 8,789
--------- --------- -----------
6,806 7,908 9,834
--------- --------- -----------
Total assets 17,649 18,021 20,906
========= ========= ===========
Financed by
Equity shareholders'
funds
Equity share capital 787 630 787
Equity share premium 28,603 23,221 28,588
Own shares reserve (4) (5) (5)
Merger reserve 20,361 20,361 20,361
Share based payment reserve 6,329 6,143 6,220
Foreign translation reserve 1,014 856 1,439
Retained earnings (45,155) (39,877) (42,936)
--------- --------- -----------
Total equity 11,935 11,329 14,454
Non-current liabilities
Contingent consideration 12 3,317 3,177 3,414
Deferred tax liability 1,384 1,357 1,458
--------- --------- -----------
4,701 4,534 4,872
--------- --------- -----------
Current liabilities
Trade and other payables 1,013 2,158 1,580
--------- --------- -----------
Total liabilities 5,714 6,692 6,452
--------- --------- -----------
Total equity and liabilities 17,649 18,021 20,906
========= ========= ===========
Condensed consolidated statement of changes in equity
For the six months ended 30 June 2017
Consolidated statement of changes in equity
Share Foreign
Equity Equity Own based translation
share share shares Merger payment Reserve Retained
capital premium reserve reserve reserve earnings Total
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
-------------- ------- ------------------------- --------- -------- --------- ------------ --------- ---------
Balance at 1
January 2016
(Audited) 567 23,220 (5) 17,626 6,084 - (37,168) 10,324
Retained loss
for the
period - - - - - - (2,657) (2,657)
Other
comprehensive
income - - - - - 856 856
Share issues 63 - 2,735 - - - 2,798
Transaction
costs (52) (52)
Exercise of
share
options - 1 - - - - - 1
Share based
payments - - - - 59 - - 59
-------------- ------- ------------------------- --------- -------- --------- ------------ --------- ---------
Unaudited at
30 June 2016
(Restated) 630 23,221 (5) 20,361 6,143 856 (39,877) 11,329
Retained loss
for the
period - - - - - - (3,059) (3,059)
Other
comprehensive
income - - - - - 583 - 583
Share issues 157 5,645 - - - - - 5,802
Transaction
costs - (278) - - - - - (278)
Exercise of - - - - - - - -
share
options
Share based
payments - - - - 77 - - 77
-------------- ------- ------------------------- --------- -------- --------- ------------ --------- ---------
Audited at 31
December 2016 787 28,588 (5) 20,361 6,220 1,439 (42,936) 14,454
Retained loss
for the
period - - - - - - (2,219) (2,219)
Other
comprehensive
income - - - - - (425) - (425)
Share issues - - - - - - - -
Transaction - - - - - - - -
costs
Exercise of
share
options - 15 1 - - - - 16
Share based
payments - - - - 109 - - 109
-------------- ------- ------------------------- --------- -------- --------- ------------ --------- ---------
Unaudited at
30 June 2017 787 28,603 (4) 20,361 6,329 1,014 (45,155) 11,935
-------------- ------- ------------------------- --------- -------- --------- ------------ --------- ---------
The reserves described above have the purposes described
below:
Own shares reserve
This reserve records the nominal value of shares purchased and
held by the Employee Benefit Trust to satisfy the future exercise
of options under the Group's share option schemes.
Merger reserve
This reserve arose as a result of a common control business
combination on the formation of the Group.
Share based payment reserve
This reserve records the credit to equity in respect of the
share based payment cost.
Foreign translation reserve
This reserve records the adjustment to equity in respect of the
retranslation of foreign subsidiary's financial statements into a
presentation currency.
Interim condensed consolidated statement of cash flows
For the six months ended 30 June 2017
Unaudited Unaudited Audited
6 Months 6 Months Year
to 30 to 30 to 31
June June December
2017 2016 2016
Restated
GBP000 GBP000 GBP000
Cash flows from operating
activities
Operating loss (2,521) (2,506) (5,182)
Adjustments for:
Depreciation of property,
plant and equipment 121 101 202
Amortisation and impairment 137 32 161
Revaluation of contingent
consideration 77 - -
Share option charge 109 59 136
(Gain) / loss on foreign
exchange (170) 396 627
Taxation (4) - 481
(Increase) in inventories (43) (150) (60)
(Increase) / decrease in
receivables (58) (14) 339
(Decrease) / increase in
payables (567) 447 (182)
--------- --------- ---------
Net cash (outflow) from
continuing operating activities (2,919) (1,635) (3,478)
Net cash (outflow) from
discontinued operating
activities - (644) (1,250)
--------- --------- ---------
Net cash (outflow) from
operating activities (2,919) (2,279) (4,728)
--------- --------- ---------
Cash flows from investing
activities
Interest received - 31 91
Funds withdrawn from term
deposits - 1,000 7,000
Acquisition of subsidiary
undertaking - (2,043) (2,043)
Investment in associate
undertaking (60) - -
Purchase of property, plant
and equipment (447) (128) (518)
--------- --------- ---------
Net cash (outflow) / inflow
from investing activities (507) (1,140) 4,530
--------- --------- ---------
Cash flows from financing
activities
Cash received from issue
of shares 16 2 5,525
Transaction costs paid
on the issue of shares - - (52)
Cash loaned to subsidiary
undertaking - - -
--------- --------- ---------
Net cash inflow from financing
activities 16 2 5,473
--------- --------- ---------
Net (outflow) / inflow
in cash and cash equivalents (3,410) (3,417) 5,275
Cash and cash equivalents
at beginning of the period 8,789 3,514 3,514
--------- --------- ---------
Cash and cash equivalents
at end of the period 5,379 97 8,789
========= ========= =========
Notes to the interim condensed consolidated financial
statements
1. General information
These unaudited interim condensed financial statements of
Itaconix plc (formerly Revolymer plc) for the six months ended 30
June 2017 were authorised for issue in accordance with a resolution
of the Board on 15 September 2017. Itaconix plc is a public limited
company incorporated in the United Kingdom whose shares are traded
on the AIM Market of the London Stock Exchange.
The figures shown above for the six months ended 30 June 2017
and 30 June 2016, and for the year ended 31 December 2016, are not
statutory accounts. A copy of the statutory accounts for each
financial year has been delivered to the Registrar of Companies.
The auditor reported on those statutory accounts and their reports
were unqualified, did not draw attention to any matters by way of
emphasis and did not contain an adverse statement under sections
498 (2) or 498 (3) of the Companies Act 2006.
Sections of this interim report, including but not limited to
the Interim Management Report, may contain forward-looking
statements with respect to certain of the plans and current goals
and expectations relating to the future financial condition,
business performance and results of the Group. These have been made
by the directors in good faith using information available up to
the date on which they approved this report. By their nature, all
forward-looking statements involve risk and uncertainty because
they relate to future events and circumstances that are beyond the
control of the Group and depend upon circumstances that may or may
not occur in the future. There are a number of factors that could
cause actual future financial conditions, business performance,
results or developments to differ materially from the plans, goals
and expectations expressed or implied by these forward-looking
statements and forecasts. Nothing in this document should be
construed as a profit forecast.
This half-yearly financial report is also available on the
Group's website at www.itaconix.com.
2. Accounting policies
The unaudited condensed financial statements are presented in
accordance with the requirements of International Accounting
Standard 34 - 'Interim Financial Reporting'.
The Group prepares its annual financial statements in accordance
with International Financial Reporting Standards as endorsed by the
European Union. Except as noted below, the condensed financial
statements have been prepared on the basis of the accounting
policies and methods of computation set out in the Annual Report
and Accounts of the Group for the year ended 31 December 2016,
which are expected to be used in the preparation of the financial
statements of the Group for the year ending 31 December 2017.
The interim condensed consolidated financial statements are
presented in sterling and all values are rounded to the nearest
thousand (GBP'000) except when otherwise indicated. The interim
condensed consolidated financial statements are prepared on the
historical cost basis except for intangible assets and contingent
consideration which has been measured at fair value.
New accounting standards
The accounting policies adopted in the preparation of the
interim condensed consolidated financial statements are consistent
with those followed in the preparation of the Group's annual
consolidated financial statements for the year ended 31 December
2016, except for the adoption of new standards and interpretations
effective as of 1 January 2017, where applicable. The Group does
not early adopt other standards, interpretations or amendments that
have been issued but are not yet effective. In the six months ended
30 June 2017, no new accounting standards were adopted.
Going concern
The financial statements have been prepared on a going concern
basis which the Directors, having undertaken appropriate
investigation as summarised below, believe continues to be
appropriate.
The Group made a loss for the period of GBP2,219k (30 June 2016
restated: GBP2,657k) (year ended 31 December 2016: GBP5,716k), had
Net Current Assets at the period end of GBP5,793k (30 June 2016
restated: GBP5,750k) (year ended 31 December 2016: GBP8,254k) and a
Net Cash Outflow from Operating Activities of GBP2,919k (30 June
2016: GBP2,279k) (year ended 31 December 2016: GBP4,728).
Primarily, the Group meets its day to day working capital
requirements through existing cash resources and had on hand cash,
cash equivalents and short term deposits at the balance sheet date
of GBP5,379k (30 June 2016: GBP6,097k) (31 December 2016:
GBP8,789).
Itaconix plc has been a loss making business in each year of its
existence to date. Whilst it expects to deliver its business plan
of becoming a profitable specialty chemicals company in the medium
term, it currently relies on its shareholders to fund the business.
Uncertainties that are specific to Itaconix's business model
include that revenue and profit growth is dependent on its products
being incorporated into its customers' products, and the rate at
which this occurs is inherently difficult to predict.
Trading and cash flow forecasts modelling a number of scenarios
were prepared for the period through to the end of 2020. The
forecasts reflect the status of the Group's current activities and
varying levels of achievement against the Board approved strategic
plan for the business, which is informed by the intent of the Board
to successfully develop its operations and move to being cash
generative by 2020.
These forecasts indicate that the Group has sufficient financial
resources to continue to fund the business, based on the current
scope of operations and meet its liabilities as they fall due, for
at least 12 months from the date of this report. The Board
recognises that it is probable that there will be a need for
further fundraising before the end of 2018 to enable the Group to
continue as a going concern and to finance its growth plans, but
anticipates that this will be completed based on the Group
delivering commercial progress (namely product launches and revenue
growth) in the intervening period, and taking into account recent
successful fundraisings.
On this basis, the Directors consider that, at this time, there
are no material uncertainties that might cast doubt upon the
appropriateness of the continuing application of the going concern
basis of preparation.
Discontinued operations
Discontinued operations are excluded from the results of
continuing operations and are presented as a single amount as
profit or loss after tax from discontinued operations in the group
statement of profit or loss.
All other Notes to the financial statements include amounts from
continuing operations, unless otherwise mentioned.
Intangible assets
Intangible assets are carried at either cost less any
accumulated amortisation and any accumulated impairment losses. The
treatment methods for each type of intangible xed asset are:
Goodwill Cost subject to annual impairment review
Intellectual property acquired Amortisation
Amortisation is calculated to write off the depreciable amount
of an intangible asset with a nite useful life on a systematic
basis over such life. Amortisation shall begin when the asset is
available for use, i.e. when it is in the location and condition
necessary for it to be capable of operating in the manner intended
by management. The rates of amortisation currently applied are:
Intellectual property arising on consolidation of
Itaconix Corporation 13 years*
*: based on the estimated life of the overall intellectual
property portfolio acquired
3. Risks and uncertainties
Itaconix plc's approach to managing the risks and uncertainties
of its business was reported in the Annual Report and Financial
Statements for the year ended 31 December 2016 and is
unchanged.
4. Cash, cash equivalents and investments
Unaudited Unaudited Audited
As at As at As at
30 June 30 June 31 December
2017 2016 2016
GBP000 GBP000 GBP000
Term deposits maturing
within one year - 6,000 -
Cash at bank and in
hand 5,379 97 8,789
--------- --------- -----------
5,379 6,097 8,789
========= ========= ===========
5. Operating Loss
For the purpose of comparison with prior periods the table below
shows the calculation of operating loss and share based payment
charges separately identified.
Unaudited Unaudited Audited
6 Months 6 Months Year
to 30 to 30 to 31
June June December
2017 2016 2016
Restated
GBP000 GBP000 GBP000
Revenue 325 25 285
Cost of sales (179) (19) (230)
--------- --------- ---------
Gross profit 146 6 55
Other operating income 2 11 38
Administrative expenses
before non-cash gain
on foreign exchange
and share-based payments
(charges) (2,730) (2,068) (4,463)
Gain / (loss) on foreign
exchange 170 (396) (676)
Share-based payments
(charge) (109) (59) (136)
--------- --------- ---------
Operating loss (2,521) (2,506) (5,182)
========= ========= =========
6. Taxation
During the six months ended 30 June 2017, the Group had a
taxation credit of GBP276k, being a provision for the current
period tax credit of GBP240k less a payment of US tax for GBP4k and
an under provision for the year ended 31 December 2016 of GBP40k
(30 June 2016: GBP232k) (year ended 31 December 2016: GBP531k).
7. Segmental analysis
Revenue by business segment:
The revenue information above is derived from the continuing
operations and excludes the Nicotine Gum segment that was disposed
in 2016 (see Note 8).
The segmental information for the six months ended 30 June 2016
has been restated as a result of the Nicotine Gum segment becoming
a discontinued operation.
The Group therefore has one segment, the Specialty Chemicals
segment, which designs and manufactures proprietary specialty
polymers to meet customers' needs in the personal and consumer
health care, homecare and industrial sectors. This segment makes up
the continuing operations above.
Net assets of the Group are attributable solely to the UK and
US.
Unaudited
6 months
to 30
Specialty June
Six months ended 30 June 2017 Chemicals 2017
GBP000 GBP000
Revenue
Sale of goods 325 325
---------- ---------
Segment revenue 325 325
---------- ---------
Results
Depreciation & amortisation 258 258
Segment loss (2,495) (2,495)
---------- ---------
Operating assets 17,412 17,412
---------- ---------
Operating liabilities 5,714 5,714
---------- ---------
Other disclosure:
Capital expenditure* 447 447
---------- ---------
Unaudited
6 months
to 30
Six months ended 30 June 2016 Specialty June
- Restated Chemicals 2016
Restated
GBP000 GBP000
Revenue
Sale of goods 25 25
---------- ---------
Segment revenue 25 25
---------- ---------
Results
Depreciation & amortisation 100 100
Segment loss (2,471) (2,471)
---------- ---------
Operating assets 18,021 18,021
---------- ---------
Operating liabilities 6,692 6,692
---------- ---------
Other disclosure:
Capital expenditure* 328 328
---------- ---------
Audited
Year
to 31
Specialty December
Year ended 31 December 2016 Chemicals 2016
GBP000 GBP000
Revenue
Sale of goods 285 285
---------- ---------
Segment revenue 285 285
---------- ---------
Results
Depreciation & amortisation 202 202
Segment loss (5,639) (5,639)
---------- ---------
Operating assets 20,761 20,761
---------- ---------
Operating liabilities 6,452 6,452
---------- ---------
Other disclosure:
Capital expenditure* 699 699
---------- ---------
The differences between the segment losses above and operating
losses in note 5 are accounted for by finance income and share of
profit/(loss) of associate.
The operating assets exclude the investment in the associate
undertaking.
*Capital expenditure consists of additions of property, plant
and equipment, intangible assets and investment properties
including assets from the acquisition of subsidiaries.
Geographical information
Revenue from external
customers Non-current assets
Unaudited Unaudited Audited Unaudited Unaudited Audited
Six Months Six Months Six Months Six Months
to 30 to 30 Year to to 30 to 30 Year to
June June 31 December June June 31 December
2017 2016 2016 2017 2016 2016
Restated Restated
GBP000 GBP000 GBP000 GBP000 GBP000 GBP000
Europe 149 21 140 467 363 419
United States 176 4 145 10,376 9,750 10,653
325 25 285 10,843 10,113 11,072
========== ========== ============ ========== ========== ============
The revenue information above is based on the location of the
customer.
Non-current assets for this purpose consist of property plant
and equipment, investment in associate undertaking, intangible
assets and goodwill.
8. Discontinued operations
In 2016, the Group divested its nicotine gum business to Alkalon
A/S, a Danish company. Results for this business are accordingly
only reported in the 2016 comparison columns below:
Unaudited Unaudited Audited
6 Months 6 Months Year
to 30 to 30 to 31
June June December
2017 2016 2016
Restated
GBP000 GBP000 GBP000
Revenue - 554 1,127
Cost of sales - (499) (948)
--------- --------- ---------
Gross profit - 55 179
Administrative expenses - (473) (787)
Impairment loss recognised
on the re-measurement to fair
value less costs to sell - - -
--------- --------- ---------
(Loss) before tax from discontinued
operations - (418) (608)
Tax benefit: Related to current
pre-tax loss - - -
Tax benefit: Related to re-measurement
to fair value less costs to
sell (deferred tax) - - -
--------- --------- ---------
(Loss) for the period from
discontinued operations - (418) (608)
========= ========= =========
Administrative expenses are stated after charging:
Depreciation -48
The net cash flows incurred by the Nicotine Gum segment are as
follows:
Unaudited Unaudited Audited
6 Months 6 Months Year
to 30 to 30 to 31
June June December
2017 2016 2016
Restated
GBP000 GBP000 GBP000
Operating - (644) (1,250)
Investing - - -
Financing - - -
--------- --------- ---------
Net cash outflow - (644) (1,250)
========= ========= =========
Earnings per share:
Unaudited Unaudited Audited
6 Months 6 Months Year
to 30 to 30 to 31
June June December
2017 2016 2016
Restated
GBP000 GBP000 GBP000
Basic loss for the year from
discontinued operations - (0.8p) (0.9p)
Diluted loss for the year from
discontinued operations - (0.8p) (0.9p)
9. Property, plant and equipment
During the six months ended 30 June 2017, the Company acquired
plant and equipment with a cost of GBP447k, (30 June 2016: GBP328k)
(year ended 31 December 2016: GBP699k).
10. Intangible assets
Customer Intellectual
Goodwill Relationships Property Total
Group GBP'000 GBP'000 GBP'000 GBP'000
Cost
At 1 January 2016 (Audited) - - - -
Acquisitions through
business combinations 5,662 29 3,031 8,722
Foreign exchange movements 530 3 327 860
-------- -------------- ------------ -------
Unaudited at 30 June
2016 (Restated) 6,192 32 3,358 9,582
Additions - - - -
Foreign exchange movements 461 (3) 251 709
-------- -------------- ------------ -------
Audited at 31 December
2016 6,653 29 3,609 10,291
Additions - - - -
Foreign exchange movements (339) - (184) (523)
-------- -------------- ------------ -------
Unaudited at 30 June
2017 6,314 29 3,425 9,768
-------- -------------- ------------ -------
Amortisation and impairment
Unaudited at 30 June
2016 (Restated) - 32 - 32
Amortisation for the
period - - 132 132
Impairment charge - - - -
Foreign exchange movements - (3) 6 3
-------- -------------- ------------ -------
Audited at 31 December
2016 - 29 138 167
Amortisation for the
period - - 134 134
Impairment charge - - - -
Foreign exchange movements - - (10) (10)
-------- -------------- ------------ -------
Unaudited at 30 June
2017 - 29 262 291
-------- -------------- ------------ -------
Net book value
Unaudited at 30 June
2017 6,314 - 3,163 9,477
-------- -------------- ------------ -------
Audited at 31 December
2016 6,653 - 3,471 10,124
-------- -------------- ------------ -------
Unaudited at 30 June
2016 (Restated) 6,192 - 3,358 9,550
-------- -------------- ------------ -------
At each reportable period end there is a requirement to
investigate whether there are any indicators of, or triggers for,
potential impairment of the value of intangible assets. As a result
of actual H1 2017 revenue falling short of management expectations,
management concluded that a review for impairment of the value of
the intangible assets was required.
The fair value of net assets (NAV) as at 30 June 2017 of the
relevant CGU, namely the itaconic acid derived product (ITADP)
business acquired in June 2016, was compared to the enterprise
value (EV) of the CGU as at 30 June 2017, as estimated using DCF
techniques in a manner consistent with the EV assessment made for
the full year 2016 audit and annual report, but based on updated
management forecasts as of July 2017. Any shortfall in the EV
compared to the NAV would form the basis of goodwill impairment,
whilst no impairment would be indicated to the extent that the EV
was equal to or greater than NAV. At the interims review stage,
management noted that there is no requirement to disclose
sensitivity analysis.
The EV was estimated using updated management forecasts that
reflect (i) actual revenue shortfalls in H1 2017 compared to
management expectations, and (ii) a reduced cost base implemented
in Q2 2017 compared to management expectations.
Consideration has also been given as to whether the discount
rate of 12.4% used at the 2016 year end remains appropriate:
-- There were no business related factors that have increased
the risk since the previous valuation (note the impact of the
change in annual sales to a more back end loaded profile in the
window to 2020 is already captured in the DCF valuation
methodology)
-- There were no macro market or economic factors that have
increased the risk since the previous valuation
-- Management has re-run its discount rate estimation as at 30
June 2017 and concluded a slightly increased weighted average cost
of capital (WACC) of 12.6% is required.
Accordingly a discount rate of 12.6% has been used in the
updated analysis.
Using this approach management has calculated an estimated EV of
$12.6m and NAV of $11.95m, and accordingly no goodwill impairment
was indicated.
The NAV includes the investment that was made in the US
manufacturing plant since acquisition and is accordingly >$1m
greater than the previous assessment.
The acquired intellectual property has been amortised over the
average life of the portfolio acquired (13 years). Management has
investigated whether there were any circumstances requiring
impairment over and above this amortisation, and concluded that
there are no business, market or economic grounds for further
impairment in the relatively short intervening period since the
previous valuation.
Overall therefore, management concluded that, having performed
reviews for potential impairment:
-- Intellectual property remains correctly valued after straight
line amortisation over 13 years.
-- Currently there are not grounds for impairment of goodwill.
11. Restatement of prior period comparatives
IFRS 3 requires fair values and liabilities acquired to be
finalised within 12 months of the acquisition date. All fair value
adjustments are required to be recorded with effect from the date
of acquisition and consequently result in the restatement of
previously reported financial results. During the second half of
2016, the Group finalised the fair values of the Itaconix
Corporation business acquired in June 2016 and this has resulted in
a restatement of the income statement and other statement of
comprehensive income and the statement of financial position
comparatives for the period to 30 June 2016. These amendments
relate to the intangible assets identified out of the purchase
price allocation process which were intellectual property and
customer relationships, the deferred tax liability recognised (in
respect of intangible assets acquired), the valuation of the
contingent consideration and the balance required to reconcile from
the net tangible assets to the fair value of the purchase price was
goodwill.
Further amendments relate to the impairment of the customer
relationships to nil and the transfer of the foreign exchange
differences arising on the net assets acquired between the date of
acquisition and the period end to other comprehensive income. The
impact of these adjustments was to increase the previously reported
loss before tax and the statutory loss for the period by GBP889k
(of which foreign exchange differences were the majority at
GBP856k).
12. Contingent consideration
At 31 December 2016 the contingent consideration to the former
shareholders of Itaconix Corporation was valued at GBP3.4m
($4.21m), and it is necessary to review this valuation at the 2017
interim period end in light of updated management expectations of
the drivers of this consideration (namely sales of ITADP) in the
period 2017 to 2020.
Management prepared an updated forecast of sales of ITADP to the
end of 2020 based on its current knowledge and reasonable
expectations and these were used to revalue the contingent
consideration, using the same methodology as adopted at the 2016
year end and in line with the contractual mechanism agreed with the
former shareholders of Itaconix Corporation.
Consideration has been given as to whether the discount rate of
10.2% remains appropriate. Management are not aware of any grounds
to change the rate and accordingly 10.2% has been used.
Management noted that at the interims stage there is no
requirement for sensitivity analysis of this valuation.
Management concluded that, on the basis of the analysis
summarised above, the contingent consideration was valued at
GBP3.3m ($4.31m), compared to GBP3.4m ($4.21m) at 31 December
2016.
13. Investment in associate undertakings
The Group acquired a 15% equity interest in Alkalon A/S
(Alkalon) on 31 October 2016. Alkalon is a Danish speciality pharma
company focused on developing and commercialising medicated chewing
gum formulations. It is a private entity not listed on any public
exchange and there is only one share class in issue (ordinary
shares) so that all shareholders hold the same class of share with
the same rights attached (i.e. there are no restrictions specific
to the Group's holding). The Group's interest in Alkalon is
accounted for using the equity method in the consolidated financial
statements. The acquisition is considered to be a long term
investment. The fair value of the investment at the period end was
arrived at as described below.
GBP'000
Fair value of Alkalon investment at 31
December 2016 145
Increase in investment at 18 May 2017 60
Reversal of previously recognised impairment
loss 22
Share of profit of equity-accounted investees,
net of tax 4
Gain on foreign exchange 6
-------
Fair value of Alkalon investment at 30
June 2017 237
-------
On 4 May 2017 SEED Capital, a 40% shareholder in Alkalon, sold
its holding, with the consent of the other shareholders, to
Metropolitan Capital Partners (MCP), a more active investor.
Shortly after this on 18 May 2017, Alkalon received a DKK3.5m
equity injection pro rata from its existing shareholders (i.e. a
purchase of a further 525,000 shares for GBP60k by Itaconix), and a
DKK2.5m shareholder loan (again pro rata) was also completed on 2
June 2017. MCP also provided additional management support to the
CEO, and a well qualified financial consultant was retained
following the departure of the previous finance resource. As at 30
June 2017, in the view of management the business was better
funded, organised and resourced than at the end of 2016. A partial
reversal of the previously recognised impairment loss was recorded
to the amount of GBP22k in relation to certain commercial
milestones being achieved, for which Itaconix was issued additional
equity taking its interest to 17.4% (after allowing for the May
2017 capital injection).
Management has reviewed the carrying value of the investment as
at 30 June 2017 and, given the factors noted above, considers that
the partial reversal of the impairment recorded in the year ended
31 December 2016 is appropriate.
Place Proportion
of incorporation of ownership
Name Principal activity and operation interest
Trading Danish
associate of
Itaconix (U.K.)
Alkalon A/S (from 31 October 2016) Ltd Denmark 15%
Trading Danish
associate of
Itaconix (U.K.)
Alkalon A/S (from 22 June 2017) Ltd Denmark 17%
14. Loss per share
Unaudited Unaudited Audited
6 Months 6 Months Year
to 30 to 30 to 31
June June December
2017 2016 2016
Restated
Weighted average number
of ordinary shares for the
purposes of basic and diluted
loss per share ('000) 78,712 57,878 69,738
========= ========= =========
15. Share based payments
The charge for share based payments for the period to 30 June
2017 was GBP109k (30 June 2016: charge 59k) (31 December 2016:
charge 136k). During the six months to 30 June 2017 4,512,460
options (30 June 2016: nil) (31 December 2016: 3,317,997) were
granted under the Revolymer LTIP 2012 scheme as either approved
options (under the HMRC approved EMI scheme) or unapproved
options.
16. Related party transactions
Transactions between the Company and its subsidiaries, which are
related parties, have been eliminated on consolidation.
Remuneration of key management personnel
The remuneration of the directors, who are considered to be the
key management personnel of the Company, is set out below in
aggregate for each of the categories specified in IAS 24 'Related
Party Disclosures'.
Unaudited Unaudited Audited
Six Months Six Months Year
to 30 to 30 to 31
June June December
2017 2016 2016
Restated
GBP000 GBP000 GBP000
Wages and salaries 319 338 783
Directors' fees invoiced
by third parties 8 8 15
Post-employment benefits 21 21 42
Equity settled share based
payment expense 43 25 50
391 392 890
========== ========== =========
Other related party transactions
The Company was invoiced during the period by IP2IPO Limited, a
company of which Mr M Townend is a director, for consultancy fees
and other expenses in respect of Mr Townend's services. Mr M
Townend is a related party by virtue of his position as a director
of the Company.
The Group invoiced Alkalon for the expenses of a common director
Robin Cridland, for attending the board meetings of Alkalon in the
period. The Group also acted as an agent for Alkalon in its conduct
of the nicotine gum business following completion of the
divestment, pending the novation and assignment of key nicotine gum
contracts in favour of Alkalon. At the date of this report, all
such novations and assignments have been completed. Alkalon is an
associate company of the Group.
Receipts Amounts Amounts
from Payments due to due from
related to related related related
parties parties parties parties
GBP000 GBP000 GBP000 GBP000
6 months to 30 June
2017
IP2IPO Services Limited - 8 4 -
Alkalon 2 - 8 44
6 months to 30 June
2016 (Restated)
IP2IPO Services Limited -84-
Year to 31 December
2016
IP2IPO Services Limited - 15 4 -
Alkalon 34 - -17
A short term loan of DKK 375,000 was made to Alkalon during the
period. The loan is due for repayment within 12 months and carries
interest at a rate of 4.5% per annum.
All related party transactions were made on terms equivalent to
those that prevail in arm's length transactions. There have been no
write-offs of related party balances during the period and there
are no provisions against any related party balances. The terms and
conditions of related party transactions are consistent with those
for other debtors and creditors.
17. Events after the reporting period
These have been reported separately in other parts of this
report and relate to commercial transactions.
INDEPENDENT REVIEW REPORT TO ITACONIX PLC
Introduction
We have been engaged by Itaconix plc (previously called
Revolymer plc) (the "Company") to review the condensed set of
financial statements in the half-yearly financial report for the
six months ended 30 June 2017 which comprises the Condensed
Consolidated Income Statement and Statement of Comprehensive
Income, Condensed Consolidated Statement of Financial Position,
Condensed Consolidated Statement of Changes in Equity, Condensed
Consolidated Statement of Cash Flows and the notes 1 to 17 to the
interim financial statements. We have read the other information
contained in the half yearly financial report and considered
whether it contains any apparent misstatements or material
inconsistencies with the information in the condensed set of
financial statements.
This report is made solely to the Company in accordance with
guidance contained in International Standard on Review Engagements
2410 (UK and Ireland) "Review of Interim Financial Information
Performed by the Independent Auditor of the Entity" issued by the
Auditing Practices Board. To the fullest extent permitted by law,
we do not accept or assume responsibility to anyone other than the
Company, for our work, for this report, or for the conclusions we
have formed.
Directors' Responsibilities
The half-yearly financial report is the responsibility of, and
has been approved by, the directors. The directors are responsible
for preparing the half-yearly financial report in accordance with
International Accounting Standards 34, "Interim Financial
Reporting," as adopted by the European Union.
As disclosed in note 2, the annual financial statements of the
company are prepared in accordance with IFRSs as adopted by the
European Union. The condensed set of financial statements included
in this half-yearly financial report has been prepared in
accordance with International Accounting Standards 34, "Interim
Financial Reporting, " as adopted by the European Union.
Our Responsibility
Our responsibility is to express to the Company a conclusion on
the condensed set of financial statements in the half-yearly
financial report based on our review.
Scope of Review
We conducted our review in accordance with International
Standard on Review Engagements (UK and Ireland) 2410, "Review of
Interim Financial Information Performed by the Independent Auditor
of the Entity" issued by the Auditing Practices Board for use in
the United Kingdom. A review of interim financial information
consists of making enquiries, primarily of persons responsible for
financial and accounting matters, and applying analytical and other
review procedures. A review is substantially less in scope than an
audit conducted in accordance with International Standards on
Auditing (UK) and consequently does not enable us to obtain
assurance that we would become aware of all significant matters
that might be identified in an audit. Accordingly, we do not
express an audit opinion.
Conclusion
Based on our review, nothing has come to our attention that
causes us to believe that the condensed set of financial statements
in the half-yearly financial report for the six months ended 30
June 2017 is not prepared, in all material respects, in accordance
with International Accounting Standard 34 as adopted by the
European Union.
Ernst & Young LLP
Manchester
18 September 2017
This information is provided by RNS
The company news service from the London Stock Exchange
END
IR DMGMLRKDGNZM
(END) Dow Jones Newswires
September 18, 2017 02:00 ET (06:00 GMT)
Itaconix (LSE:ITX)
Historical Stock Chart
From Apr 2024 to May 2024
Itaconix (LSE:ITX)
Historical Stock Chart
From May 2023 to May 2024